A novel histology-based risk prediction tool, HIBRID, combines machine learning and circulating tumor DNA analysis to transform colorectal cancer management. Published in Nature Communications, this approach integrates advanced computational methods with molecular diagnostics, enabling precise assessment of patient risk and personalized treatment guidance. The fusion of AI and liquid biopsy heralds a new era in oncology, enhancing early detection and therapeutic stratification.